Jodi Daniel joins Crowell & Moring LLP

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JODI DANIEL joined the firm Crowell & Moring LLP as a partner in its Health Care Group.

Daniel is the former director of the Office of Policy in the Office of the National Coordinator for Health Information Technology at the Department of Health and Human Services. Daniel served for a decade as the director at the ONC and 15 years at HHS, where she worked on changes in health information privacy and health information technology.

As the first senior counsel for health information technology in the Office of the General Counsel of HHS, Daniel developed HHS’s foundational legal strategies and coordinated all legal advice regarding health IT for HHS.

“Jodi literally wrote the book—and all the rules— governing health information technology, including the complex HIPAA privacy and enforcement rules,” said John Brennan, Jr., chair of the firm’s Health Care Group. “Her experience in setting the regulatory framework and policies for both technology providers and adopters has supported innovation in areas including mobile health, remote devices and telehealth, and that insight will be of enormous value to our clients as they operate in this highly regulated space.”

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login